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Abstract
Background: Cholesterol pathways play an important role at multiple stages during the HIV-1 infection cycle. Here,
we investigated the role of cholesterol trafficking in HIV-1 replication utilizing Niemann-Pick Type C disease (NPCD)
cells as a model system.
Results: We used a unique NPC2-deficient cell line (NPCD55) that exhibited Gag accumulation as well as
decreased NPC1 expression after HIV infection. Virus release efficiency from NPCD55 cells was similar to that from
control cells. However, we observed a 3 to 4-fold enhancement in the infectivity of virus released from these cells.
Fluorescence microscopy revealed accumulation and co-localization of Gag proteins with cholesterol in late
endosomal/lysosomal (LE/L) compartments of these cells. Virion-associated cholesterol was 4-fold higher in virions
produced in NPCD55 cells relative to virus produced in control cells. Treatment of infected NPCD55 cells with the
cholesterol efflux-inducing drug TO-9013171 reduced virus infectivity to control levels.
Conclusions: These results suggest cholesterol trafficking and localization can profoundly affect HIV-1 infectivity by
modulating the cholesterol content of the virions.
Background
Cellular cholesterol plays a critical role in various stages
of the HIV-1 replication cycle. HIV-1 fusion, entry,
assembly, and budding occur at cholesterol-enriched
microdomains called lipid rafts [1-4]. The HIV-1 acces-
sory protein, Nef, has been shown to induce many genes
involved in cholesterol biosynthesis and homeostasis
[5,6]. Depletion of virion-associated cholesterol by beta-
cyclodextrin compromises viral structural integrity and
significantly decreases both the quantity and infectivity
of virions released from infected cells [7,8]. Treatment
of HIV particles with cholesterol-sequestering com-
pounds inhibits virus entry into host cells [9,10].
Previous studies have shown that Nef inhibits the
activity of ATP-binding cassette transporter A1
(ABCA1) in HIV-infected macrophages. The inhibition
of ABCA1 leads to suppression of cholesterol efflux and
an accumulation of intracellular cholesterol [11]. In
turn, this effect increases the cholesterol content of the
virions. The proteins implicated in Niemann-Pick Type
C (NPC) disease, NPC1 and NPC2, are responsible for
the egress of intracellular cholesterol and glycosphingo-
lipids from late endosomal/lysosomal (LE/L) compart-
ments [12-14]. Patients carrying mutations in either
NPC1 or NPC2 display phenotypes that are clinically
and biochemically indistinguishable. The two NPC pro-
teins have been recently shown to function in the same
pathway [15-17]. The hallmark phenotype of cells defi-
cient in either NPC1 or NPC2 is accumulation of unes-
terified LDL-derived cholesterol in LE/L compartments
[18-21].
HIV-1 Gag accumulates in the cholesterol-laden LE/L
compartments of NPC1-deficient cells and virus release
is dramatically reduced [22]. LE compartments can
serve as sites for HIV-1 assembly and budding [23-26]
and host proteins that reside in these compartments are
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that NPC proteins mediate cholesterol transport from
the LE/L compartment to other compartments, we
sought to utilize NPC disease as a model for investigat-
ing whether this cholesterol transport pathway is essen-
tial for HIV-1 assembly and release. Fibroblasts from
four donors of each cell type- normal, NPC1-deficient
(NPC1D), and NPC2-deficient (NPC2D), were used to
study HIV-1 replication. Cells from one donor
(NPCD55) whose HIV replication phenotype was strik-
ingly different from cells of other donors provided a
useful tool for our studies. Our findings demonstrate a
link between intracellular cholesterol transport and loca-
lization and HIV-1 infectivity.
Results
Expression levels of HIV-1 Gag and NPC proteins in
fibroblasts
Because of the inherent cholesterol transport defect in
NPCD cells, they were used to examine the impact of
reduced cholesterol transport capability on HIV-1 repli-
cation. Normal, NPC2D, and NPC1D fibroblasts were
infected with the single-cycle HIV-1 VSVG-NL4.3. The
VSVG-NL4.3 virus was made by pseudotyping env-
deleted NL4.3 with VSV G protein. Gag p55 and p24
expression was measured by Western blot analysis (Fig-
ure 1A). Intracellular Gag was measured via flow cyto-
metry and the mean fluorescence intensity (MFI) data
showed that across infected cell types there was no sig-
nificant difference in Gag expression (Figure 1B).
Because of the genetic mutations in NPC2D and
NPC1D, we expected NPC2D (Figure 1A, lanes 5-8) and
NPC1D (Figure 1A, lanes 9-12) fibroblasts to express
much lower levels of NPC2 and NPC1, respectively,
when compared to controls (Figure 1A, lanes 1-4). The
NPC2 bands observed in lanes 5 and 7 represent
mutated forms of protein that are non-functional (Cor-
iell Repository, Camden, NJ). Interestingly, the results in
lane 8 show a striking decrease in NPC1 expression
upon infection of one of the NPC2D cell lines with
HIV-1 (Figure 1A). This result is in contrast to other
NPC2D and normal cells that normally show no change
or an increase in NPC1 expression upon HIV infection.
Normal and NPC2D cells showed approximately a 1:1
ratio of p55 to p24 (Figure 1A, lanes 2-7). Along with
cells from normal donors, we included cells from
NPC1D donors as controls. In Figure 1A, the results in
lane 12 are consistent with our previous findings show-
ing Gag accumulation in cells from this NPC1 donor.
The reduction in NPC1 expression upon infection of
NPC2D cells in lane 8 of Figure 1A provided a model
system to study HIV-1 assembly and release in the con-
text of low or absent expression of both NPC1 and
NPC2. In these cells the export of cholesterol from LE/
L compartments is presumably very low or completely
impaired. Therefore, our studies focused on characteriz-
ing the HIV phenotype in this cell line, henceforth
designated as NPCD55.
HIV-1 Gag protein accumulates in cholesterol-laden LE/L
compartments of NPCD55 cells
We used dual-label immunofluorescence and filipin
staining to visualize Gag, LE/L, and cholesterol in HIV-
1-infected cells. Results in infected normal cells showed
marginal and diffuse staining of HIV-1 Gag and choles-
terol (filipin staining) (Figure 2A-B). Gag showed a high
degree of colocalization with cholesterol in LE/L com-
partments of NPC1D cells (Figure 2H) as previously
reported [22]. HIV-1-infected NPC2D cells displayed a
Gag localization pattern similar to NPC1D cells (Figure
2L). Gag accumulated in the perinuclear region of the
cell and colocalized with cholesterol in LE/L compart-
ments (Figure 2I-L). As in NPC1D and NPC2D cells,
Gag colocalized with cholesterol in NPCD55 cells. How-
ever, the staining intensity of these two components was
much higher in NPCD55 cells (Figure 2M-P). Previous
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Figure 1 Protein expression analysis of normal and NPC-
deficient cells after HIV-1 infection. Cells were uninfected or
infected with VSVG-HIV-1 and harvested 96 h post-infection. (A)
NPC2, NPC1, and b-actin protein expression was detected via
Western blotting in uninfected and infected cells. Gag expression
was also detected in the infected cells. (B) At 96 h post infection,
cells were fixed and stained with KC57-FITC (anti-Gag). Flow
cytometry was performed and mean fluorescence intensity (MFI) is
shown.
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proteins is impaired in NPCD cells [29-32]. Our data
appear to indicate that like these host proteins, HIV-1
Gag transport is retarded in NPCD55 cells and the pro-
tein accumulates in LE/L compartments.
Cholesterol content of virions released from NPCD55 cells
is enhanced
Colocalization of Gag with cholesterol in LE/L compart-
ments of NPCD55 cells could promote the incorpora-
tion of cholesterol into budding virions. Therefore, we
quantified the cholesterol content of virions released
from HIV-1-infected NPCD55 and HIV-1-infected nor-
mal cells. HIV-1 infection has been shown to increase
cholesterol biosynthesis in infected cells [29]. We mea-
sured intracellular cholesterol in normal and NPCD55
cells 96 h post-infection. As expected, the intracellular
cholesterol content of uninfected NPCD55 cells was
much higher than that of normal cells (Figure 3A). Both
cell types showed a slight increase in free cholesterol
after infection (Figure 3A). Virions released from
NPCD55 cells contained approximately 4-fold more
cholesterol than virions released from normal cells (Fig-
ure 3B). In a recent report describing AnxA6 depen-
dence on Ca
2+ for recruitment into lipid rafts in a
fibroblast cell line (L1) derived from an NPCD patient,
Domon et al. demonstrated an increased GM1 content
in the L1 cells [30]. This ganglioside is highly enriched
in lipid rafts and serves as a useful marker for lipid rafts
in solubilized membrane flotation assays [31,32]. HIV-1
budding and assembly occurs primarily at lipid rafts and
Gag has been shown to associate with these sites
[33-35]. HIV-1 Nef has been shown to increase HIV-1
infectivity via a lipid raft-dependent mechanism [36,37].
We hypothesized that the enhanced cholesterol content
of virions released from NPCD55 cells might be corre-
lated with increased lipid rafts in these cells. In mem-
brane flotation assays, GM1 could be detected as early
as fraction 1 of NPCD55 cells whereas GM1 expression
was not seen until fraction 4 of normal cells (Figure
3C). A plot of the GM1 staining intensities in the frac-
t i o n sf r o mt h ef l o t a t i o na s s a y ss h o w e dt h a tt h eo v e r a l l
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Figure 2 Gag localizes to LE/L compartments in NPC-deficient cells. At 96 h post-infection with HIV-1, fibroblasts were stained and analyzed
by fluorescence microscopy to assess Gag localization. Intracellular cholesterol (blue) was visualized by staining the cells with filipin dye (A, E, I,
M). LysoTracker was used to stain late endosomes/lysosomes (red) (C, G, K, O) and HIV-1 Gag protein (green) (B, F, J, N) was stained with KC57-
FITC.
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that of normal cells (Figure 3D). This result is consistent
with a higher content of lipid rafts in NPCD55 cells
compared to the control cells.
Enhanced infectivity of virions produced in NPCD55 cells
Virion-associated cholesterol is critical for HIV-1 infec-
tivity [38,39]. In light of the results showing increased
cholesterol in HIV-1 from NPCD55 cells, we examined
the infectivity of virus produced from these cells. HIV-1
was produced in a panel of normal and NPC2D cell
lines. The virus-containing supernatants were collected
and titrated onto TZM-bl reporter cells. These cells
express beta-galactosidase and luciferase under the con-
trol of the HIV-1 LTR and can be used to study HIV-1
infectivity. The virus produced in NPCD55 cells showed
a striking increase in infectivity compared to virus
produced in the other five cell lines (Figure 4A). The
much higher infectivity of NPCD55-derived virus was
highly reproducible. When TZM-bl cells were infected
with purified virus produced in normal and NPCD55
cells, virions from NPCD55 cells yielded 3-fold higher
luciferase activity than virions from normal cells (Figure
4B). These results indicate that HIV produced in
NPCD55 cells is more highly infectious than virus pro-
duced in normal and other NPC2D cells.
TO-901317 treatment stimulates cholesterol efflux and
reduces infectivity of HIV-1 virions produced in NPCD55
cells
Results obtained thus far demonstrate that in HIV-1-
infected NPCD55 cells Gag colocalizes with cholesterol
in LE/L compartments, virions produced in these cells
incorporate more cholesterol, and the virions released
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Figure 3 Free cholesterol and lipid raft content of normal and NPCD55 cells.( A) Cellular cholesterol was measured in uninfected and HIV-
1-infected Normal (filled) and HIV-1-infected NPCD55 (slashed) cells by AmplexRed assay. Cholesterol concentration was normalized to total
protein. Error bars represent triplicate experiments. Values are relative to the normal uninfected control which was arbitrarily set to 1. (B) Virus
produced from each cell type was concentrated by centrifugation through a 20% sucrose cushion. The cholesterol content of the virus was
measured by AmplexRed assay and input was normalized by p24 concentration. (C) Lipid raft fractions were collected for normal and NPCD55
cells and loaded for dot blot analysis. Membranes were probed with cholera toxin B to detect GM1. The samples were normalized by protein
concentration and volume. (D) Dot intensities for the blot shown were quantified using ChemiDoc XRS and Quantity One software.
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Page 4 of 10are more infectious (Figures 2, 3B and 4B). Earlier stu-
dies from our laboratory and others have shown that
the cholesterol content of HIV-1 can affect infectivity of
the virus [40-42]. Therefore we sought to determine
whether enhanced infectivity of HIV-1 from NPCD55
cells was due to higher cholesterol content. To this end,
we stimulated cholesterol efflux in normal and NPCD55
cells by treating the cells with the synthetic nonsteroidal
LXR agonist, TO-901317. TO-901317 treatment of
NPC1-deficient fibroblasts results in an increase in
ABCA1 expression, marked increase in cholesterol
efflux, and reduction of unesterified cholesterol in the
LE/L compartment [43]. We infected normal and
NPCD55 cells according to the protocol described above
except that at 24 h post-infection cells were cultured in
complete medium or medium supplemented with 5 μM
TO-901317 for 72 hrs. ABCA1 expression was signifi-
cantly enhanced upon TO-901317 treatment of both
normal and NPCD55 cells (Figure 5A, lanes 3 and 6).
Induction of cholesterol efflux resulted in increased pre-
sence of both unprocessed (p55) and processed (p24)
gag in HIV-1-infected NPCD55 cells, but not in HIV-1-
infected normal cells (Figure 5A, lanes 5-6). Stimulation
of cholesterol efflux resulted in a 20% reduction of free
cholesterol in HIV-1-infected normal cells and almost
2-fold decrease in HIV-1-infected NPCD55 cells (Figure
5B). Similar levels of decrease were found when choles-
terol was measured in HIV-1 released from normal and
NPCD55 cells (Figure 5C). We next examined the infec-
tivity of virus released from control and TO-901317-
treated cells. As seen in Figure 5D, TO-901317 treat-
ment of NPCD55 cells reduced the infectivity of released
HIV-1 by more than 2-fold, down to a level close to that
of virus released from control cells. Based on these data
we conclude that the enhanced infectivity of virus
released from NPCD55 cells is due largely to the
increased amount of free cholesterol in the LE/L com-
partments in these cells that results in higher virion-
associated cholesterol. Our findings are in agreement
with previous work in which the induction of ABCA1
by TO-901317 resulted in inhibition of HIV-1 replica-
tion [44].
Discussion
We have identified an NPC2 deficient cell line
(NPCD55) that loses expression of NPC1 upon infection
by HIV-1. This allowed us to examine the role of a criti-
cal cholesterol homeostatic pathway, export of choles-
terol from endosomes, in HIV-1 replication. Our data
show that when both major proteins involved in this
pathway are poorly expressed, HIV-1 acquires much
more cholesterol and is much more infectious. The
fluorescence microscopy analysis demonstrates that
HIV-1 Gag proteins localize to cholesterol-laden LE/L
compartments in NPCD55 cells. The strong co-localiza-
tion of Gag with cholesterol to LE/L compartments of
NPCD55 cells correlated with a much higher cholesterol
content in virions released from these cells. These data
are consistent with prior studies showing that HIV
assembly occurs on lipid raft membranes as are found
in late endosomes [3,25,45]. Induction of cholesterol
efflux showed that free cholesterol levels within the LE/
L compartments in NPCD55 cells was likely responsible
for the increased cholesterol content in virions produced
in these cells. NPCD55 cells not only had increased free
cholesterol, but also showed evidence of a marked
enhancement of lipid rafts. Prior studies provide evi-
dence that lipid rafts accumulate in LE/L compartments
in NPCD cells [46,47]. Neither an overall increase in
intracellular cholesterol nor increased lipid raft content
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Figure 4 Infectivity of virus produced from normal and
NPCD55 cells.( A) Virus containing supernatants from three normal
and NPC2D fibroblasts were titrated onto TZM-bl indicator cells. At
48 h post-infection, the cells were harvested and luciferase assay
was performed to measure virus infectivity. Luciferase activity was
normalized to virus input. (B) TZM-bl cells were infected with 5 ng
of purified virus released from Normal and NPCD55 cells. Infectivity
was measured by luciferase activity and normalized to Normal cells,
which was arbitrarily set to 1. Error bars are representative of three
independent infections.
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Page 5 of 10alone would account for such a significant increase in
virus infectivity as observed in virus produced from
NPCD55 cells. However, the correct subcellular localiza-
tion of unesterified cholesterol is probably critical to
HIV infectivity. Since the cell’s LE compartments are
major sites of HIV-1 assembly and budding, the accu-
mulation of cholesterol and lipid rafts in LE/L compart-
ments may explain the enhanced infectivity of HIV-1
released from NPC2D55 cells.
Our work initially included cells from four NPC2D
donors. Because NPC1 and NPC2 function in the same
pathway and HIV-1 replication is inhibited when NPC1
is absent, we wanted to test whether HIV-1 replication
was also inhibited in the absence of NPC2. Interestingly,
we did not observe the drastic reduction in virus release
from NPC2D cells as we had previously demonstrated
with NPC1D cells [22]. When NPC2D cells were
infected, virus release efficiency was similar to controls
(data not shown). The infectivity of virions produced in
NPC2D cells was slightly higher than the infectivity of
virions produced in control cells; however, the infectivity
of virions produced in NPCD55 cells was strikingly
higher than that of virus from control cells and from
other NPC2D cell lines. We then focused our studies on
utilizing NPCD55 cells to further define how cholesterol
transport pathways contribute to HIV-1 infectivity.
Since all NPC2D cells lacked a functional NPC2 protein
and displayed the characteristic NPC phenotype, we
expected that the infectivity of virions produced from
these cells would be similar.
The NPC1 gene contains sterol response elements and
expression of the protein is modulated by SREBPs
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Figure 5 Induction of cholesterol efflux attenuates the enhancement in HIV-1infectivity in NPCD55 cells.( A) Normal and NPCD55 cells
were treated with 5 μM TO-901317 at 24 h post-infection and cultured for 72 h in the presence of the compound. At 96 h post-infection the
cells were harvested and ABCA1, Gag, and b-actin expression was detected by Western blotting analysis. All samples were loaded on the same
gel. (B) AmplexRed assay was performed to measure free cholesterol content of untreated (filled) and TO-901317-treated (slashed) cells.
Cholesterol content was normalized to protein concentration. (C) AmplexRed assay was performed to measure virion-associated cholesterol from
purified virus produced in untreated (filled) and TO-901317-treated (slashed) infected cells. Virion-associated cholesterol content was normalized
to p24 concentration. (D) TZM-bl reporter assay was performed to measure virus infectivity when cholesterol efflux was induced via TO-901317
stimulation. The r values were calculated by performing student T-test (*denotes < 0.05).
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Page 6 of 10[48-50]. Thus, the decrease in NPC1 expression in
NPCD55 cells after infection with HIV-1 was unex-
pected since sterol response genes are upregulated after
HIV-1 infection [5,29]. Interestingly, NPC1 expression
was increased as expected in other cell lines after HIV
infection. It is not clear why NPC1 expression was lost
after HIV-1 infection of NPCD55 cells. Mutations in the
promoter region may have affected the ability of SREBPs
to modulate NPC1 expression. Previous reports demon-
strate that the intronic microRNA, miR-33, is located
within the gene encoding SREBP-2 and that these mole-
cules are coordinately regulated [51,52]. Further, miR-33
inhibits ABCA1 mediated cholesterol efflux and strongly
suppresses NPC1 protein expression. Therefore, the
decreased expression of NPC1 could be miR33-mediated
via induction of SREBP expression upon HIV-1 infection
of NPCD55 cells. HIV-1 Nef has been shown to impair
cholesterol efflux by directly interacting with ABCA1
and dowregulating ABCA1 expression [11]. Though the
mechanism is unclear, the interaction between Nef and
ABCA1 is not required for post-translational degrada-
tion of ABCA1 [53]. NPC1 protein expression could
also be decreased upon HIV-1 infection in a manner
similar to ABCA1 downregulation. However, this does
not explain why loss of NPC1 did not occur in other
HIV-1-infected NPC2D cells.
Another possibility for differences among NPC2D cells
is the level of cholesterol esterification activity among
the cells. NPCD55 cells were characterized as having
undetectable cholesterol esterification (Coriell Institute
for Medical Research, Coriell Cell Repositories, unpub-
lished), whereas cells from other NPC2D donors show
some level of cholesterol esterification activity. The ratio
of free cholesterol to cholesterol esters may be different
between NPCD55 cells and other NPC2D cells, with
NPCD55 cells containing more unesterified cholesterol.
This is important since unesterified cholesterol is incor-
porated into budding virions, and the lack of esterase
activity would enhance the pool of unesterified choles-
terol. Free cholesterol, but not cholesterol esters, can
also suppress induction of sterol response genes. The
infectivity of HIV produced in other NPC2D cell lines
was generally similar to that of virus produced in nor-
mal cell lines. Thus the cholesterol accumulation pheno-
type alone of NPCD does not appear to cause changes
in HIV-1 infectivity. The dramatic enhancement of
infectivity in virus produced in NPCD55 cells was asso-
ciated with a remarkable and unique co-localization of
free cholesterol and HIV-1 Gag protein. This probably
produced an ideal setting for incorporation of the criti-
cal lipid by the virus. However, we cannot rule out the
possibility that NPCD55 cells may have other unidenti-
fied genetic mutations that could affect the function of
other proteins involved in regulating HIV-1 infectivity.
In summary, our findings demonstrate that defects in
the NPC1/NPC2 pathway of cholesterol efflux from late
endosomes can profoundly affect HIV-1 infectivity and
highlight the contribution of intracellular cholesterol
transport and localization to virus infectivity.
Methods
Cells
Fibroblasts from healthy- normal donors (GM00500,
GM09503, GM00409, and GM00499) as well as patients
carrying mutations in the NPC1 (GM00110, GM17913,
GM17921, GM03123) or NPC2 (GM17910, GM18439,
GM18445, GM18455) genes were obtained from Coriell
Repositories (Coriell Institute for Medical Research,
Camden, NJ). The fibroblasts were maintained in Dul-
becco modified Eagle medium (Gibco-BRL/Life Tech-
nologies, Gaithersburg, MD) supplemented with 15%
defined fetal bovine serum (FBS-D) (HyClone, Logan,
UT), L-glutamine, and 10 mM HEPES (pH 7.2). Cell
viability was assessed by trypan blue exclusion. TZM-bl
HIV-1 indicator cells were obtained from the NIH AIDS
Research and Reference Reagent Program (Germantown,
MD) and maintained in DMEM supplemented with 10%
fetal calf serum (FCS), L-glutamine, and 10 mM HEPES
(pH 7.2), and 100 U/ml penicillin and streptomycin
(cDMEM). 293 T human embryonic kidney cells were
maintained in DMEM supplemented with L-glutamine,
and 10 mM HEPES (pH 7.2), and 10% FCS (HyClone,
Logan, UT).
Virus
Vesicular stomatitis virus envelope glycoprotein G
(VSV-G)-pseudotyped HIV-1 was prepared using 293T
cells. Cells were co-transfected with pNL4.3-GFP plas-
mid (kind gift from Dr. Robert Silicano, Johns Hopkins
School of Medicine) and the VSV-G expression vector
pHEF-VSV-G using the calcium phosphate transfection
method. Briefly, at 48 h post-transfection the culture
supernatants containing virus particles were collected
a n df i l t e r e dt h r o u g ha0 . 4 5μm filter. The virus was
quantified by p24 ELISA and used for direct infection of
fibroblasts.
Western blot analysis
Intracellular protein expression was analyzed by stan-
dard Western blot using the NuPAGE gel electrophor-
esis system (Invitrogen, Carlsbad, CA). Briefly, cells were
lysed on ice for 30 min in RIPA buffer (50 mM Tris-
HCl, Adjust to pH 7.41, 50 mM NaCl, 1 mM PMSF, 1
mM EDTA, 5 μg/ml protinin, 5 μg/ml Leupeptin, 1%
Triton x-100, 1% Sodium deoxycholate, 0.1% SDS) sup-
plemented with protease inhibitors (Roche catalogue no.
1873580). Lysates were then clarified of cell debris by
centrifugation at 13,000 rpm at 4°C for 20 min. Lysates
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Page 7 of 10were run on 4-12% Bis-Tris gels, and then transferred
onto nitrocellulose using a semi-dry transfer apparatus
(BioRad). Membranes were blocked for 30 min in
Superblock (Invitrogen, Carlsbad, CA) before probing
with primary antibodies. Following washing 3 times in
phosphate buffered saline containing 0.05% Tween-20
(PBS-T), the membranes were probed with HRP conju-
gated secondary antibodies. Chemiluminescent substrate
(ECL, GE Healthcare Life Sciences) was used for
detection.
Antibodies
The antibodies used in this study were rabbit polyclonal
antibodies: anti-NPC1 (Novus Biologicals), anti-ABCA1
(Novus Biologicals), and anti-b-actin (Sigma-Aldrich).
Rabbit polyclonal antibody against NPC2 was a kind gift
from Dr. Peter Lobel (UMDNJ-Robert Wood Johnson
Medical School, Piscataway, NJ). Gag monoclonal anti-
p24 was purchased from Millipore (Temecula, CA). Sec-
ondary antibodies (HRP conjugated goat anti-rabbit or
mouse heavy- and light-chain specific) were purchased
from Jackson ImmunoResearch Laboratories (West-
grove, PA).
Infection of fibroblasts
Normal and NPC-deficient fibroblasts were seeded (3 ×
10
5 cells) in 10-cm culture plates in cDMEM. Cells were
a l l o w e dt og r o wf o r1 2 - 1 6ha n di n f e c t e dw i t h3μgo f
VSV G-NL4.3, normalized for HIV-1 capsid p24. After
24 h, the cells were washed to remove virus and cul-
tured in fresh media. At 96 h post infection, the cells
and supernatants were harvested. Supernatants were col-
lected and stored at -80°C for further analysis. Cells
were trypsinized, washed 3 times in PBS, and prepared
for Western blot or flow cytometry analysis. Infection
efficiencies were determined by flow cytometry. Briefly,
cells were fixed with 2% paraformaldehyde, permeabi-
lized using 0.1% saponin, and stained with fluorophore-
conjugated antibodies. Stained cells were analyzed using
the Becton FACSCalibur flow cytometer (Cell Quest
software). Virus produced from these cells was quanti-
fied by p24 ELISA and normalized to the percentage of
cells that were positive for Gag.
Cholesterol efflux
Fibroblasts were cultured and infected with VSVG-
NL4.3 as previously described. At 24 h post infection,
the input virus was removed and the cells were washed
3 times in PBS. Cells were then cultured in medium
alone, medium supplemented with 15% Lipoprotein
Deficient Serum (LPD-S), or medium containing 5 μM
TO-901317 (Sigma-Aldrich, St. Louis, MO). Cells and
supernatants were harvested 96 h post infection.
Virus titer determination
Virus released from infected cell cultures was measured
using an ELISA developed in our laboratory to measure
viral p24 antigen (sensitivity 50-2000 pg/mL).
Cell staining and immunofluorescence assay
Cells were grown on 35-mm glass bottom dishes (Mat-
Tek Corporation, Ashland, MA). For LysoTracker Red
staining, cells were incubated for 2 h at 37°C with 75
nM LysoTracker Red DND-99 and then fixed for 15
min in 2% paraformaldehyde in PBS. The cells were per-
meabilized with 5% normal goat serum in BD Cytofix/
Cytoperm solution (BD Biosciences, San Diego, CA).
Gag and cholesterol staining was performed using
KC57-FITC (Beckman Coulter, Inc., Fullerton, CA) and
filipin (Sigma-Aldrich, St. Louis, MO) respectively. The
reagents were diluted in BD Cytofix/Cytoperm solution
and added to the cells for 30 min at room temperature.
Cells were washed 2 times in PBS and anti-fade solution
was applied before imaging. Photographs were taken
using a Nikon TE2000 wide-field microscope (Nikon
Instruments, Melville, NY) with a 40X oil objective. The
FITCx was utilized to eliminate cross excitation between
DAPI and FITC.
Flow cytometry
After cells were stained and fixed as previously
described, the cells were washed in PBS and resus-
pended in 1 mL FACS buffer (1XPBS, 5% FCS, and 0.1%
sodium azide). The cells were then analyzed on a FACS-
Calibur (Becton Dickson) flow cytometer.
Infectivity assay
TZM-bl cells were plated in 96-well microtiter plate at a
density of 12.5 × 10
3/100 μl. After 24 h, cells were
infected for 12 h with virus generated from infected
fibroblasts. The input virus was removed and the cells
were washed 3 times in PBS and maintained under nor-
mal culture conditions. At 24 h-post infection, cells
were washed 3 times in PBS and luciferase assay was
performed using a luciferase reporter gene assay system
(Luc-Screen kit; Applied Biosystem, Foster City, CA).
Relative luciferase units were normalized to input p24
values.
Cholesterol quantification
Cellular and virion associated cholesterol was measured
using the Amplex
®Red Cholesterol Assay Kit (Invitro-
gen, Carlsbad, CA). Samples were processed in accor-
dance with the manufacturer protocol. To measure
unesterified cholesterol, the cholesterol esterase enzyme
was eliminated from the reaction mixture. Cholesterol
content for cells and virions was normalized to protein
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Page 8 of 10and p24 concentration. Protein concentrations of cell
lysates were determined by BCA assay (Fisher, Waltham,
MA). Virus p24 concentrations were measured by p24
ELISA.
Isolation of lipid rafts
Lipid rafts were isolated from cell lysates as previously
described by Popik et al. [54]
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